Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

12 de novembro de 2026 atualizado por: Cugene Inc.

A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion

Tipo de estudo

Intervencional

Inscrição (Estimado)

65

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Admin Cugene
  • Número de telefone: 1(781) 893-5800
  • E-mail: admin@cugene.com

Locais de estudo

    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • NEXT Virginia

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Signed and dated informed consent.
  2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
  3. At least 1 measurable lesion according to RECIST v1.1.
  4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
  7. Life expectancy of ≥3 months.
  8. Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.

Exclusion Criteria

  1. Rapidly progressing disease or disease requiring urgent alternative medical intervention.
  2. Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
  3. Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
  4. Concurrent participation in another interventional therapeutic clinical trial.
  5. Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
  6. Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
  7. Unresolved clinically significant toxicities from prior anticancer therapy.
  8. Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
  9. Active or clinically significant infection except as specified in the protocol.
  10. Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
  11. Known hypersensitivity or significant allergic reaction to biologics or its components.
  12. Recent vaccination, except as permitted by the protocol.
  13. Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part A Dose Escalation

CUG279 will be administered at multiple ascending dose levels

CUG279 will be administered intravenously according to the protocol

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of dose limiting toxicities (DLTs)
Prazo: From the first dose up to 21 days post-dose

The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A.

From the first dose up to 21 days post-dose
Incidence and severity of treatment-emergent adverse events (TEAEs)
Prazo: From first dose through 90 days after the last dose

The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of serious adverse events (SAEs)
Prazo: From first dose through 90 days after the last dose

The number and percentage of participants with SAEs will be assessed.

From first dose through 90 days after the last dose
Clinically significant changes in safety laboratory parameters from baseline
Prazo: From first dose through 90 days after the last dose

Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Prazo: From first dose through 90 days after the last dose

Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in vital signs from baseline
Prazo: From first dose through 90 days after the last dose

Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of TEAEs leading to dose modifications
Prazo: From the first dose through the last dose; up to 1 year

The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed.

From the first dose through the last dose; up to 1 year

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Maximum observed plasma concentration (Cmax) of CUG279
Prazo: From first dose through 90 days after the last dose

The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Trough plasma concentrations (Ctrough) of CUG279
Prazo: From first dose through 90 days after the last dose

The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose

From first dose through 90 days after the last dose
Area under the concentration-time curve (AUC) of CUG279
Prazo: From first dose through 90 days after the last dose

The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data.

From first dose through 90 days after the last dose
Terminal half-life (T1/2) of CUG279
Prazo: From first dose through 90 days after the last dose

The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Systemic clearance (CL) of CUG279
Prazo: From first dose through 90 days after the last dose

The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Volume of distribution (Vz) of CUG279
Prazo: From first dose through 90 days after the last dose

The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 antibodies (ADA)
Prazo: From first dose through 90 days after the last dose

Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Prazo: From first dose through 90 days after the last dose

Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined

From first dose through 90 days after the last dose
Objective response rate (ORR)
Prazo: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Disease control rate (DCR)
Prazo: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Time to response (TTR)
Prazo: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1

From the first dose through study completion or until disease progression; up to 1 year
Duration of response (DoR)
Prazo: From the first dose through study completion or until disease progression; up to 1 year

Time from first documented CR or PR to disease progression will be determined per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Best overall response (BOR)
Prazo: From the first dose through study completion or until disease progression; up to 1 year

Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Progression-free survival (PFS)
Prazo: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

5 de novembro de 2026

Conclusão Primária (Estimado)

30 de março de 2029

Conclusão do estudo (Estimado)

30 de março de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

19 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CUG279-P101
  • IND 179862 (U.S. FDA IND) (Outro identificador: FDA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .